Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies

被引:14
作者
Fergusson, Dean A. [1 ,2 ]
Wesch, Neil L. [1 ]
Leung, Garvin J. [1 ,2 ]
MacNeil, Jenna L. [1 ]
Conic, Isidora [1 ]
Presseau, Justin [1 ,3 ]
Cobey, Kelly D. [3 ,4 ,5 ]
Diallo, Jean-Simon [6 ,7 ]
Auer, Rebecca [2 ,6 ,7 ]
Kimmelman, Jonathan [8 ]
Kekre, Natasha [2 ]
El-Sayes, Nader [2 ,6 ]
Krishnan, Ramya [2 ,6 ]
Keller, Brian A. [2 ,6 ]
Ilkow, Carolina [6 ,7 ]
Lalu, Manoj M. [1 ,9 ,10 ,11 ]
机构
[1] Ottawa Hosp Res Inst, BLUEPRINT Translat Res Grp, Clin Epidemiol Program, 501 Smyth Rd,POB 201B, Ottawa, ON K1H 8L6, Canada
[2] Univ Ottawa, Fac Med, Ottawa, ON K1H 8M5, Canada
[3] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON K1H 8M5, Canada
[4] Ottawa Hosp Res Inst, Ctr Journalol, Ottawa, ON K1H 8L6, Canada
[5] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland
[6] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada
[7] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada
[8] McGill Univ, Biomed Eth Unit, Montreal, PQ H3A 0G4, Canada
[9] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada
[10] Univ Ottawa, Ottawa Hosp, Dept Anesthesiol & Pain Med, Ottawa, ON K1H 8L6, Canada
[11] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada
关键词
DESIGN AFFECTS OUTCOMES; CANCER; METAANALYSIS; VIROTHERAPY;
D O I
10.1016/j.omto.2019.05.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irreproducibility of preclinical findings could be a significant barrier to the "bench-to-bedside" development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design. Using the NIH Principles and Guidelines for Reporting Preclinical Research, a core set of seven recommendations, we evaluated the completeness of reporting of preclinical OV studies. We also developed an evidence map identifying the current trends in OV research. A systematic search of MEDLINE and Embase identified all relevant articles published over an 18 month period. We screened 1,554 articles, and 236 met our a priori-defined inclusion criteria. Adenovirus (43%) was the most commonly used viral platform. Frequently investigated cancers included colorectal (14%), skin (12%), and breast (11%). Xenograft implantation (61%) in mice (96%) was the most common animal model. The use of preclinical reporting guidelines was listed in 0.4% of articles. Biological and technical replicates were completely reported in 1% of studies, statistics in 49%, randomization in 1%, blinding in 2%, sample size estimation in 0%, and inclusion/exclusion criteria in 0%. Overall, completeness of reporting in the preclinical OV therapy literature is poor. This may hinder efforts to interpret, replicate, and ultimately translate promising preclinical OV findings.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
[41]   ACTIVE IMMUNOTHERAPY Oncolytic Virus Therapy Using HSV-1 [J].
Todo, Tomoki .
GLIOMA: IMMUNOTHERAPEUTIC APPROACHES, 2012, 746 :178-186
[42]   Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy [J].
Menotti, Laura ;
Avitabile, Elisa .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) :1-26
[43]   Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model [J].
Friedman, Avner ;
Lai, Xiulan .
PLOS ONE, 2018, 13 (02)
[44]   Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review [J].
Jiang, Shan ;
Chai, Huihui ;
Tang, Qisheng ;
Shi, Zhifeng ;
Zhou, Liangfu .
DISCOVER ONCOLOGY, 2023, 14 (01)
[45]   Engineered Measles Virus as a Novel Oncolytic Therapy Against Prostate Cancer [J].
Msaouel, Pavlos ;
Lankov, Lanko D. ;
Allen, Cory ;
Morrs, John C. ;
von Messling, Veronika ;
Cattaneo, Roberto ;
Koutsilieris, Michael ;
Russell, Stephen J. ;
Galanis, Evanthia .
PROSTATE, 2009, 69 (01) :82-91
[46]   Oncolytic virus and CAR-T cell therapy in solid tumors [J].
Ponterio, Eleonora ;
Haas, Tobias Longin ;
De Maria, Ruggero .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[47]   Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β [J].
Naik, S. ;
Nace, R. ;
Barber, G. N. ;
Russell, S. J. .
CANCER GENE THERAPY, 2012, 19 (07) :443-450
[48]   Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer [J].
Beguin, Jeremy ;
Foloppe, Johann ;
Maurey, Christelle ;
Laloy, Eve ;
Hortelano, Julie ;
Nourtier, Virginie ;
Pichon, Christelle ;
Cochin, Sandrine ;
Cordier, Pascale ;
Huet, Helene ;
Quemeneur, Eric ;
Klonjkowski, Bernard ;
Erbs, Philippe .
MOLECULAR THERAPY-ONCOLYTICS, 2020, 19 :57-66
[49]   Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies [J].
Nettelbeck, Dirk M. ;
Leber, Mathias F. ;
Altomonte, Jennifer ;
Angelova, Assia ;
Beil, Julia ;
Berchtold, Susanne ;
Delic, Maike ;
Eberle, Juergen ;
Ehrhardt, Anja ;
Engeland, Christine E. ;
Fechner, Henry ;
Geletneky, Karsten ;
Goepfert, Katrin ;
Holm, Per Sonne ;
Kochanek, Stefan ;
Kreppel, Florian ;
Krutzke, Lea ;
Kuehnel, Florian ;
Lang, Karl Sebastian ;
Marchini, Antonio ;
Moehler, Markus ;
Muehlebach, Michael D. ;
Naumann, Ulrike ;
Nawroth, Roman ;
Nueesch, Jurg ;
Rommelaere, Jean ;
Lauer, Ulrich M. ;
Ungerechts, Guy .
VIRUSES-BASEL, 2021, 13 (08)
[50]   Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy [J].
Wei, Yumeng ;
Pu, Xinlin ;
Zhao, Ling .
ONCOLOGY REPORTS, 2017, 37 (06) :3159-3166